ENUM selling off there "intellectual property isn't anything new here.
Pieris Pharmaceutical(PIRS) on the NYSE which is trading around 4.72, has had an agreement with Enumeral to buy their PD-1 antibody. They couldn't get anything done by May 31 so the deal was terminated.